Stoke Therapeutics, Inc. (STOK) Stock Grade

About Stoke Therapeutics, Inc.'s fundamentals

Stoke Therapeutics is a biotechnology company with a market capitalization of $1.9 billion that reported exceptional revenue growth of 404.5% year-over-year, indicating rapidly expanding commercial activity or recent product launches. Despite this growth, the company posted a net loss with a negative net margin of -3.7% on its latest annual statement, though it maintained positive free cash flow, suggesting operational expenses are being managed while the business scales. The company does not currently pay a dividend and lacks sufficient profitability to calculate a meaningful price-to-earnings ratio.